上海盟科药业股份有限公司 自愿披露关于公司核心产品专利 获得期限补偿的公告

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. has received approval for a patent term compensation for its core product, extending the patent protection period for its antibacterial drug, Kantizolam Tablets, until August 6, 2033, which enhances its market exclusivity and competitive edge [1][2]. Summary by Sections Patent Information - The patent number is ZL200880020610.0, and it pertains to an antibacterial compound used for treating bacterial infections, specifically Kantizolam Tablets. The patent was applied for on August 6, 2008, and is owned by Shanghai Mengke Pharmaceutical Co., Ltd. [1]. Patent Term Compensation Decision - The National Intellectual Property Administration has granted a patent term compensation of 1,826 days, extending the original patent expiration date from August 6, 2028, to August 6, 2033. The compensation is applicable only to the new drug approved by the State Council's drug regulatory authority and its related indications [1]. Impact on the Company - The approval of the patent term compensation for Kantizolam Tablets provides an additional five years of market protection, significantly enhancing the product's exclusive sales window in the domestic market and improving the company's core competitiveness. However, this approval is not expected to have a significant short-term impact on the company's performance [2].